|
||
|
|
|
||
|
|
This Figure presents essentially the same information as in the previous Figure, but in graphic form. The data in the left-hand side of the Figure are from a single, representative study. [81] On the right are the average TTR values for 5 representative studies.[82][83][84][85][86] Both graphic summaries basically show the same thing: that only about half of the time do patients with nonvalvular AFib who are treated and adherent to warfarin have serum values within the therapeutic range – ie, TTRs average about 50%.
Reiffel JA. Am J Med 2013; 126: 00-00.
[81] Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
[82] Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4:22-29.
[83] Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244-252.
[84] Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008;6:1647-1654.
[85] Sarawate C, Sikirica MV, Willey VJ, Bullano MF, Hauch O. Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis. 2006;21:191-198.
[86] McCormick D, Gurwitz, JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161:2458-2463.